secwatch.observer — SEC 8-K summary
======================================

Issuer:     DiaMedica Therapeutics Inc. (DMAC)
CIK:        0001401040
Form:       8-K
Filed at:   2023-03-28T23:59:59+00:00
Accession:  0001437749-23-008188
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DiaMedica reports FY2022 cash $33.5M, updates on ReMEDy2 clinical hold progress
-------------------------------------------------------------------------------

- Cash and investments of $33.5M at Dec 31, 2022 vs $45.1M at end of 2021; cash runway into Q4 2024.
- R&D expenses fell to $7.8M in 2022 from $8.8M; G&A expenses rose to $6.2M from $4.9M.
- FDA clinical hold on ReMEDy2 remains; Part 1 in-use study completed, supports dose revision to avoid hypotension; Part 2 data due April 2023.
- Phase 1C SAD study of DM199 started in Australia to confirm IV dose; enrollment underway, preliminary data expected May 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401040/000143774923008188/0001437749-23-008188-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401040/000143774923008188/dmtp20230327_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-008188

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer